Literature DB >> 8188448

Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity.

E Albengres1, S Urien, J Barre, P Nguyen, F Bree, P Jolliet, J P Tillement, R S Tsai, P A Carrupt, B Testa.   

Abstract

Six oxicams, sudoxicam, isoxicam, piroxicam, tenoxicam, meloxicam and lornoxicam, were compared in an attempt to understand why, despite close chemical structures, two of them were associated with an increased risk of toxicity in patients. Different factors have been revealed which may explain these differences. A weak association constant to human serum albumin (HSA), together with a high plasma concentration, favours a rapid increase in unbound concentration (Cu) when total plasma concentration rises (peak of absorption). Pathological states may enhance this increase when both HSA plasma concentration is decreased and free fatty acid concentrations are increased. However, the main cause of toxicity may be the existence in some subjects of HSA natural mutants whose ability to bind oxicams is markedly lower than normal.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8188448

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  7 in total

1.  Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).

Authors:  Cassondra Bauer; Patrice Frost; Stephen Kirschner
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

Review 2.  Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.

Authors:  P Jolliet; N Simon; F Brée; S Urien; A Pagliara; P A Carrupt; B Testa; J P Tillement
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

Review 4.  Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.

Authors:  J A Balfour; A Fitton; L B Barradell
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

5.  Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions induced by meloxicam.

Authors:  Yong-Qiu Zheng; Wei Wei; Yu-Xian Shen; Min Dai; Li-Hua Liu
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

6.  Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs.

Authors:  Brian J Smith; Stephen M Kirschner; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-09-02       Impact factor: 1.232

Review 7.  Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.

Authors:  N M Skjodt; N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.